MedTrace Logo

Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation

NCT04535193 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-05-07

No results posted yet for this study

Summary

This is a Phase 1/2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervation.

Conditions

Interventions

DRUG

18F-mFBG for intravenous administration

Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent

Sponsors & Collaborators

  • Mount Sinai Hospital, New York

    collaborator OTHER

  • Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

    lead INDUSTRY

Principal Investigators

  • Vikram Agarwal, MD · Mount Sinai Morningside

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-05
Primary Completion
2025-03-07
Completion
2025-03-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04535193 on ClinicalTrials.gov